[PTLA] Portola Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 25.06 Change: 6.33 (33.8%)
Ext. hours: 24.85 Change: -0.21 (-0.84%)

chart PTLA

Refresh chart

Strongest Trends Summary For PTLA

PTLA is in the medium-term up 37% in 2 months. In the long-term down -57% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -2.28% Sales Growth - Q/Q-2.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.53% ROE-36.59% ROI
Current Ratio9.89 Quick Ratio Long Term Debt/Equity Debt Ratio0.1
Gross Margin Operating Margin-1592.24% Net Profit Margin-1595.01% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities113.04 M Cash From Investing Activities9.44 M Cash From Operating Activities-47.15 M Gross Profit
Net Profit-46.91 M Operating Profit-46.5 M Total Assets486.3 M Total Current Assets403.45 M
Total Current Liabilities40.79 M Total Debt Total Liabilities67.32 M Total Revenue2.36 M
Technical Data
High 52 week48.22 Low 52 week15.46 Last close31.05 Last change0.13%
RSI75 Average true range1.08 Beta1.7 Volume8.33 M
Simple moving average 20 days8.06% Simple moving average 50 days28.83% Simple moving average 200 days6.1%
Performance Data
Performance Week0.29% Performance Month20.16% Performance Quart61.05% Performance Half18.06%
Performance Year-31.03% Performance Year-to-date59.07% Volatility daily2.27% Volatility weekly5.07%
Volatility monthly10.39% Volatility yearly35.99% Relative Volume1513.75% Average Volume1.72 M
New High New Low

News

2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

2019-03-20 17:00:00 | Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors

2019-03-12 10:27:43 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-03-06 16:10:00 | Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference

2019-03-05 08:04:00 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-03-01 16:47:09 | Edited Transcript of PTLA earnings conference call or presentation 1-Mar-19 1:30pm GMT

2019-03-01 13:57:59 | Portola Pharmaceuticals Inc PTLA Q4 2018 Earnings Conference Call Transcript

2019-03-01 12:45:00 | Why Portola Pharmaceuticals Skyrocketed 15.3% Today

2019-03-01 07:38:44 | European CHMP Adopts Positive Opinion on Ondexxya™ andexanet alfa Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent

2019-02-28 09:28:13 | Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million

2019-02-22 10:30:03 | Will Portola Pharmaceuticals PTLA Report Negative Earnings Next Week? What You Should Know

2019-02-19 08:25:00 | Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments

2019-02-08 08:05:30 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-02-07 16:03:22 | Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding

2019-02-01 11:45:01 | Is There An Opportunity With Portola Pharmaceuticals, Inc.’s NASDAQ:PTLA 22.17% Undervaluation?

2019-02-01 08:30:00 | Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019

2019-01-30 08:43:01 | Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019

2019-01-29 08:04:50 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-01-28 09:23:16 | Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer

2019-01-15 08:04:07 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-01-09 08:04:25 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-01-07 08:11:44 | Why Portola Pharmaceuticals Rose 8.09% on January 4

2019-01-03 14:01:01 | Take Profits on This Pharma Stock

2019-01-02 09:25:02 | Portola Up as Large-Scale Andexxa Production Gets FDA Nod

2018-12-31 15:59:00 | Portola stock shoots higher after FDA approval

2018-12-31 15:19:26 | U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process

2018-12-18 08:30:00 | Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019

2018-12-17 14:58:37 | Portola Pharmaceuticals, Inc. NASDAQ:PTLA: Is Breakeven Near?

2018-12-13 16:45:00 | Here's Why Portola Pharmaceuticals Fell 11% Today

2018-12-13 00:07:12 | Is Portola Pharmaceuticals Inc PTLA A Good Stock To Buy?

2018-12-12 10:15:03 | Portola PTLA Down as CHMP Defers Review Date for Ondexxya

2018-12-11 14:04:05 | Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today

2018-12-11 11:13:00 | Portola Pharma shares slide 6% on news of delay in EU review of treatment for bleeding

2018-12-11 07:00:00 | CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ andexanet alfa

2018-12-04 07:30:00 | Recent Analysis Shows Portola Pharmaceuticals, Xenia Hotels & Resorts, WestRock, Newtek Business Services, The ExOne, and VMware Market Influences — Renewed Outlook, Key Drivers of Growth

2018-12-03 21:15:00 | Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies

2018-11-24 08:05:16 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2018-11-15 08:04:27 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2018-11-09 10:21:28 | Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

2018-11-09 09:16:00 | Here's What Portola Pharmaceuticals Is Saying About Its Future

2018-11-08 07:05:00 | Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Global Blood Therapeutics

2018-11-07 23:31:10 | Edited Transcript of PTLA earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-07 19:30:12 | Portola Pharmaceuticals PTLA Reports Q3 Loss, Tops Revenue Estimates

2018-11-07 18:26:26 | Portola Pharmaceuticals: 3Q Earnings Snapshot

2018-11-07 16:05:00 | Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-06 16:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

2018-11-06 08:05:10 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2018-11-01 17:30:00 | Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-11-01 16:03:00 | Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology ASH Annual Meeting

2018-10-27 08:06:17 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.